Recombinant Anti-CD89 x Anti-EGFR Bispecific Antibody (scFv-CH3) contains two chains. The anti-CD89 scFv is fused to the Knob-CH3 domain via a hinge region and the same as the anti-EGFR scFv to the Hole-CH3 domain, or vice versa. The KIH CH3 domains can facilitate to form a heterodimer and this bivalent binding leads to improvement in avidity. This BsAb can retarget macrophages to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Non-small cell lung cancer (NSCLC); Solid tumors therapy.